Cyclohexyl-griselimycin Is Active against Mycobacterium abscessus in Mice.

Area of Science:

• Antimicrobial drug discovery
• Mycobacterial infections
• Drug-resistant pathogens

Background:

• Tuberculosis (TB) drug discovery efforts have yielded promising preclinical candidates.
• Nontuberculous mycobacteria (NTM), particularly Mycobacterium abscessus, pose significant challenges due to intrinsic drug resistance.
• Limited therapeutic options exist for M. abscessus infections, necessitating novel antibiotic development.

Purpose of the Study:

• To evaluate the efficacy of cyclohexyl-griselimycin against Mycobacterium abscessus.
• To assess the potential of repurposing TB drug discovery compounds for NTM treatment.
• To explore cyclohexyl-griselimycin as a novel lead compound for M. abscessus infections.

Main Methods:

• In vitro susceptibility testing of cyclohexyl-griselimycin against M. abscessus.
• In vivo efficacy assessment using a mouse model of M. abscessus infection.
• Evaluation of an oral cyclodepsipeptide compound.

Main Results:

• Cyclohexyl-griselimycin demonstrated significant in vitro activity against M. abscessus.
• The compound showed efficacy in a preclinical mouse model of M. abscessus infection.
• Oral administration of cyclohexyl-griselimycin was effective.

Conclusions:

• Cyclohexyl-griselimycin is an effective preclinical candidate against Mycobacterium abscessus.
• Repurposing compounds from tuberculosis drug discovery accelerates the development of novel antibiotics for M. abscessus.
• This study supports a strategy of screening TB drug discovery leads for NTM applications.